52 related articles for article (PubMed ID: 21879967)
1. Extralabel use of cabergoline in the treatment of a pituitary adenoma in a rat.
Mayer J; Sato A; Kiupel M; DeCubellis J; Donnelly T
J Am Vet Med Assoc; 2011 Sep; 239(5):656-60. PubMed ID: 21879967
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas.
Knoepfelmacher M; Danilovic DL; Rosa Nasser RH; Mendonça BB
Fertil Steril; 2006 Sep; 86(3):719.e15-8. PubMed ID: 16952513
[TBL] [Abstract][Full Text] [Related]
3. Cabergoline decreases somatotroph adenoma size: a case report.
Rickels MR; Snyder PJ
Pituitary; 2004; 7(2):107-10. PubMed ID: 15761660
[TBL] [Abstract][Full Text] [Related]
4. Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.
Leese G; Jeffreys R; Vora J
Postgrad Med J; 1997 Aug; 73(862):507-8. PubMed ID: 9307745
[TBL] [Abstract][Full Text] [Related]
5. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.
Casulari LA; Naves LA; Mello PA; Pereira Neto A; Papadia C
Horm Res; 2004; 62(6):300-5. PubMed ID: 15557761
[TBL] [Abstract][Full Text] [Related]
6. Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy.
Vieira Neto L; Wildemberg LE; Moraes AB; Colli LM; Kasuki L; Marques NV; Gasparetto EL; de Castro M; Takiya CM; Gadelha MR
Clin Endocrinol (Oxf); 2015 May; 82(5):739-46. PubMed ID: 25418156
[TBL] [Abstract][Full Text] [Related]
7. One-year follow-up evaluation of magnetic resonance imaging of the brain in dogs with pituitary-dependent hyperadrenocorticism.
Bertoy EH; Feldman EC; Nelson RW; Dublin AB; Reid MH; Feldman MS
J Am Vet Med Assoc; 1996 Apr; 208(8):1268-73. PubMed ID: 8635969
[TBL] [Abstract][Full Text] [Related]
8. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
9. Pituitary apoplexy within a macroprolactinoma.
Watt A; Pobereskin L; Vaidya B
Nat Clin Pract Endocrinol Metab; 2008 Nov; 4(11):635-41. PubMed ID: 18797434
[TBL] [Abstract][Full Text] [Related]
10. Clinical presentation of pituitary adenomas in rats.
Vannevel JY
Vet Clin North Am Exot Anim Pract; 2006 Sep; 9(3):673-6. PubMed ID: 16931389
[TBL] [Abstract][Full Text] [Related]
11. Remission in Cushing disease with cabergoline.
Gopal R; Bandgar T; Menon P; Shah N
Ann Saudi Med; 2008; 28(3):224-5. PubMed ID: 18500188
[No Abstract] [Full Text] [Related]
12. A case of postprandial cluster-like headache with prolactinoma: dramatic response to cabergoline.
Negoro K; Kawai M; Tada Y; Ogasawara J; Misumi S; Morimatsu M
Headache; 2005 May; 45(5):604-6. PubMed ID: 15953282
[TBL] [Abstract][Full Text] [Related]
13. Cabergoline treatment in a case of macroprolactinoma after delivery.
Falsetti L
Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
[TBL] [Abstract][Full Text] [Related]
14. Resolution of third nerve palsy following treatment of prolactinoma with cabergoline.
Harries AM; Gittoes NJ; Mitchell RD
Acta Neurochir (Wien); 2010 Oct; 152(10):1741-3. PubMed ID: 20623359
[TBL] [Abstract][Full Text] [Related]
15. Pituitary macroadenomas and macroadenocarcinomas in dogs treated with mitotane for pituitary-dependent hyperadrenocorticism: 13 cases (1981-1986).
Nelson RW; Ihle SL; Feldman EC
J Am Vet Med Assoc; 1989 Jun; 194(11):1612-7. PubMed ID: 2753785
[TBL] [Abstract][Full Text] [Related]
16. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience.
Vargas-Ortega G; González-Virla B; Balcázar-Hernández L; Arreola-Rosales R; Benitez-Rodríguez FJ; López Félix B; Mercado M
Arch Endocrinol Metab; 2022 Sept 08; 66(4):506-511. PubMed ID: 35758837
[TBL] [Abstract][Full Text] [Related]
19. Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapy.
Iglesias P; Macho LP; Díez JJ
Age Ageing; 2004 Jul; 33(4):410-2. PubMed ID: 15136289
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas.
Bhansali A; Walia R; Dutta P; Khandelwal N; Sialy R; Bhadada S
Indian J Med Res; 2010 Apr; 131():530-5. PubMed ID: 20424304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
